-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NXC-736 in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NXC-736 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: NXC-736 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NXC-736 in Alopecia Areata
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NXC-736 in Alopecia Areata Drug Details: NXC-736 is under development for the treatment of nonalcoholic steatohepatitis,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NXC-736 in Ulcerative Colitis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NXC-736 in Ulcerative Colitis Drug Details: NXC-736 is under development for the treatment of nonalcoholic steatohepatitis,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NXC-736 in Non-Alcoholic Steatohepatitis (NASH)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.NXC-736 in Non-Alcoholic Steatohepatitis (NASH)Drug Details:NXC-736 is under development for the treatment of nonalcoholic steatohepatitis, transplant rejection,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Amelenodor in Ulcerative Colitis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Amelenodor in Ulcerative ColitisDrug Details:Amelenodor (NX-13) is under development for the treatment of inflammatory bowel disease...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – NXC-736
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry NXC-736 Drug Details NXC-736 is under development for the treatment of nonalcoholic steatohepatitis, transplant rejection,...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – NX-13
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry NX-13 Drug Details NX-13 is under development for the treatment of inflammatory bowel disease...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.